Quantcast

First Rheumatoid Arthritis Patient to Climb Mount Everest

April 5, 2011

Jeffrey Gottfurcht Sets Off on Dream Quest to Conquer the World’s Highest Mountain to Inspire Dreams of Children Similarly Afflicted

San Francisco, CA (PRWEB) April 4, 2011

Jeffrey Gottfurcht may have only one climb left. Buoyed by a personal quest and the goal of inspiring others, the 38-year-old founder of The Jeffrey Gottfurcht Children’s Arthritis Foundation (JGCAF) and former finance executive, plans to be the first patient with rheumatoid arthritis to climb Mount Everest at 29,035 feet.

Gottfurcht, who lives in the San Francisco area, will begin his journey to the world’s highest mountain accompanied by a guide and a Sherpa on what is typically an eight week climb, subject to favorable weather conditions.

Gottfurcht would be the first climber with rheumatoid arthritis to scale Everest. He has been climbing mountains since his teens; at 28 he was diagnosed with this autoimmune disease, which attacks the joints and causes inflammation, joint pain and stiffness, while leading to fatigue and permanent joint damage. Without treatment, patients with rheumatoid arthritis (RA) may suffer deformity, disability and diminished quality of life ““ and would certainly not feel up to the grueling task of climbing Mount Everest.

“In coping with rheumatoid arthritis, an incurable disease, I have been moved to reach out to others who are similarly affected, especially children, who have to put everything on hold, including their dreams. My goal of climbing Mount Everest is to inspire those with rheumatoid arthritis, whether adults or children, to reach higher and achieve their dreams,” Gottfurcht said.

Amazingly, even after his RA diagnosis, Gottfurcht conquered other peaks, including Mt. Elbrus (Russia, 18,500 feet), Mt. Rainier (Washington, 14,400 feet) and Pico de Orizaba (Mexico, 18,400 feet). Due to severe joint pain and immobility, Gottfurcht had not been able to climb for the first two years following his diagnosis but vowed that he would one day climb again … and he did. His determination and will to climb again were in direct response to the original diagnosis. His was an aggressive form of the disease, which most likely would render him functionally immobile within ten years. A prognosis he simply refused to accept.

A key supporter of Gottfurcht’s climb is Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and pain. Gottfurcht uses the company’s medication Nyloxin, an over-the-counter treatment for chronic pain, to aid in relieving the pain and inflammation that accompanies rheumatoid arthritis. According to Deitsch, “As a sponsor of Jeffrey on his historic Everest climb, we want people to become aware of rheumatoid arthritis and Jeffrey’s Foundation. We want all chronic pain sufferers — and medical professionals — to understand that, if Nyloxin can be effective in this extreme use and in this extreme activity, imagine how effective it will be to manage the everyday pain and inflammation of rheumatoid arthritis.”

Gottfurcht, the father of three young children, created the JGCAF, a wish-granting organization that grants dreams “”ranging from requests to help cover educational and medical costs to requests for big screen computers or Wii systems to help a child affected by arthritis to cope with limited visibility or mobility. Some dream requests are from juvenile arthritis patients seeking a moment to connect with a revered sports or pop culture icon to help them endure the intense pain of everyday life and medical treatment.

Children age 4 to 21 afflicted with juvenile arthritis are eligible for a “wish grant.” The Foundation encourages a member of a child’s medical team (doctor, nurse, social worker or child-life specialist), a parent, sibling or legal guardian to propose a wish for a child suffering from juvenile arthritis. Children with juvenile arthritis may send in their dream request directly. After JGCAF receives the dream request, the Foundation contacts the child’s treating physician to determine if the child is medically eligible for the requested wish””and then works with its network of supporters to make the wish come true.

About JGCAF

The Jeffrey Gottfurcht Children’s Arthritis Foundation was founded by Jeffrey Gottfurcht as a way to inspire, educate and generate awareness of both rheumatoid and juvenile idiopathic arthritis, as those suffering optimistically await a cure. In 2002, at the age of 28, Gottfurcht was diagnosed with RA and after undergoing years of treatment; he wanted to share his determination to fight the disease while bringing joy, strength and support to children and young adults similarly afflicted. A wish-granting Foundation, JGCAF accepts referrals for dreams from parents, guardians, siblings, members of the medical community, and directly from children suffering from juvenile rheumatoid arthritis. The Foundation’s Dream Team helps select dreams that are prudent and possible and assists in making them come true. Help us fulfill a dream of a child living with Juvenile Arthritis today. For more information or to make donations please call 310.855.3745 or visit http://www.JGCAF.org.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV). Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin and Nyloxin. For additional information about Nutra Pharma, visit http://www.NutraPharma.com.

Note: To respect the privacy of its dream recipients, the JGCAF does not disclose their full names.

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/04/prweb5216714.htm


Source: prweb



comments powered by Disqus